Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery

Figures & data

Table 1 Preoperative tumor volume and time to tumor doubling in size and growth rate

Case	Sex	Age (Years)	Preoperative follow up (months)	Initial tumor volume (cm^3)	Preoperative tumor volume (cm^3)	TTD (months)	Growth rate (mm/year)
1	Male	61	7.5	20.9	36.3	8.3	5.24
2	Female	75	16.4	2.04	3.93	7.1	2.96
3	Male	73	28.5	9.21	12.8	10.2	4.27
4	Male	78	22.8	4.32	8.66	28.6	2.13
5	Female	71	13.7	9.35	16.9	14.6	3.30
6	Male	75	8.6	9.49	25.3	17.7	2.93
7	Female	70	48.3	2.25	4.11	48.1	0.87
8	Male	60	52.8	1.55	5.46	61.3	3.61
9	Female	80	35.7	5.32	6.66	25.4	1.38
10	Male	76	54.2	30.5	44	62.3	1.71
11	Male	76	41.2	0.61	4.9	22.7	4.24
12	Female	73	19.1	11.5	27.1	58.2	1.47
13	Male	52	14.7	9.88	15.6	27.6	17.62
14	Female	35	56.6	11.2	13.4	18.8	1.94
15	Male	77	6.8	0.59	1.1	5.5	2.32
16	Male	72	6.5	0.14	0.7	31.5	2.79
17	Male	74	6.5	0.52	3.58	24.6	2.27
18	Male	65	6.6	11.6	19.2	9.9	5.71
19	Male	35	7.5	2.55	5.08	7.5	3.87
20	Male	57	59.9	1.9	11.7	22.8	5.71
21	Male	42	41.2	13.6	26.6	42.7	2.48
22	Male	59	6.9	8.62	11.5	16.7	2.25
23	Male	56	45.3	8.42	47.4	18.1	10.50
24	Male	50	23.1	1.2	3.45	15.1	2.82
25	Male	65	74.8	1.2	10.6	23.7	0.52
26	Male	58	23.1	1.05	3.23	14.2	2.74
27	Male	72	28.8	5.32	15.9	18.3	6.38
28	Male	61	20.2	1.6	3.94	15.6	3.20
29	Female	73	9.1	2.59	4.32	12.3	4.14
30	Male	70	39.9	0.48	1.78	21.1	1.38
31	Male	61	21.9	2.6	12.8	9.5	12.20
32	Male	65	11.3	8.16	14.4	13.7	5.68
33	Male	71	24.7	9.12	12.8	49.6	1.18
34	Female	52	6.9	2.83	4.32	11.4	0.64

Abbreviation: TTD, time to tumor doubling.

Table 2 Histopathological diagnosis and clinical outcome

Case	Histological subtype	Grade	Tumor number	Postoperative follow up (months)	Clinical outcome recurrence (+/−)
1	Clear	2	1	25	–
2	Clear	2	1	15.2	–
3	Papillary	Unknown	1	12.4	–
4	Clear	Unknown	1	6.3	–
5	Clear	2	1	26.1	–
6	Papillary	3	1	37	–
7	Clear	1	1	33.6	–
8	Clear	1	1	35.7	–
9	Clear	1	1	32.3	–
10	Clear	1	1	33.4	–
11	Clear	1	1	28.6	–
12	Papillary	2	1	41.8	–
13	Clear	1	1	75.7	–
14	Clear	2	1	27.6	–
15	Clear	2	1	64.7	–
16	Clear	1	1	11.8	Death (LC)
17	Papillary	2	1	23.8	–
18	Clear	2	1	25.1	–
19	Clear	1	1	16.9	–
20	Papillary	3	1	19.6	–
21	Clear	2	1	32	–
22	Clear	2	1	30.1	–
23	Clear	1	1	30.3	–
24	Clear	1	1	45.7	–
25	Multilocular clear	3	1	42.3	–
26	Oncocytoma	–	1	–	–
27	Clear	2	1	54.3	Death (RCC)
28	Clear	1	1	56.5	Death (PC)
29	Oncocytoma	–	1	–	–
30	Clear	1	1	80.1	–
31	Clear	3	1	81.4	–
32	Clear	1	1	14.8	–
33	Clear	2	1	122.8	–
34	Clear	2	1	88.7	–

Abbreviations: Clear, clear cell carcinoma; LC, lung cancer; Multilocular clear, multilocular clear cell renal cell carcinoma; Papillary, papillary cell carcinoma; PC, pancreas carcinoma; RCC, renal cell carcinoma.

Table 3 Renal cell carcinoma growth rate

	TTD (months) mean (range)	P value
Total no of cases	34
Histological grade of clear cell carcinoma		0.068*
Grade 1 (n = 13)	28.5 (7.5–62.3)
Grade 2 (n = 11)	18.4 (5.5–149.6)
Grade 3 (n = 1)	9.5
Histologic subtype		ns**
Clear cell carcinoma (n = 26)	23.5 (5.5–62.3)
Papillary cell carcinoma (n = 5)	26.7 (10.2–58.2)
Multilocular clear cell (n = 1)	23.7
Oncocytoma (n = 2)	13.3 (12.3–14.2)

Notes:

* Grade 1 versus grade 2;

** clear cell carcinoma vs papillary cell carcinoma.

Abbreviations: ns, not significant; TTD, time to tumor doubling.